Quarterly ResultAug 5, 2026, 04:49 PM
Geron H1 Product Revenue $109.24M; Net Loss Reduced by 44%
AI Summary
Geron Corporation reported a net loss of $(16.68) million for Q2 2026, with product revenue reaching $57.47 million, a 17.27% increase year-over-year. For the first six months of 2026, the company significantly reduced its net loss by 44% to $(20.32) million, while product revenue grew by 23.52% to $109.24 million. The company also provided updates on its Pharmakon Loan Agreement, where Tranche B and C loans are no longer available, and ongoing legal proceedings related to RYTELO's commercial potential.
Key Highlights
- Product revenue for Q2 2026 increased 17.27% to $57.47 million.
- Net loss for Q2 2026 was $(16.68) million, or $(0.02) per share.
- Product revenue for H1 2026 increased 23.52% to $109.24 million.
- Net loss for H1 2026 decreased 43.9% to $(20.32) million.
- Cash and cash equivalents stood at $62.64 million as of June 30, 2026.
- Net cash used in operating activities for H1 2026 was $(78.73) million.
- Pharmakon Loan Tranche B and C loans are no longer available.
- Securities class action lawsuit regarding RYTELO's commercial potential continues.
Price Impact
More from GERN